The FDA approved an expanded indication for Janssen's oral androgen receptor inhibitor Erleada, or apalutamide, with the addition of coverage for men with metastatic castration-sensitive prostate cancer.
Expanded indication approved by FDA for Erleada for prostate cancer
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.